Related Experiment Video

Updated: Apr 4, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.5K

Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies

Andrew Lee1, Jeremy Rajanayagam2, Mona Abdel-Hady3

  • 1Birmingham Children's Hospital, Liver Unit, Birmingham, United Kingdom ; The University of Queensland, School of Medicine, Brisbane, Australia.

Journal of Clinical and Translational Hepatology
|September 11, 2015
PubMed

Insights

New direct-acting antivirals revolutionize hepatitis C treatment, offering improved outcomes. This review summarizes current pediatric hepatitis C care and explores novel therapies for children.

Area of Science:

  • Hepatology
  • Virology
  • Pediatric Infectious Diseases

Background:

  • Viral hepatitis C (HCV) presents a significant global health burden.
  • Direct-acting antivirals (DAAs) represent a major advancement in HCV treatment, offering higher cure rates and improved safety profiles.
  • Pediatric HCV treatment options are less developed than adult options, with limited clinical trial data for newer DAAs.

Purpose of the Study:

  • To review the current standard of care for chronic hepatitis C in children.
  • To summarize evidence-based treatment guidelines for pediatric HCV infection.
  • To explore the potential use of novel direct-acting antiviral agents in pediatric populations.

Main Methods:

  • Literature review of current treatment guidelines for pediatric hepatitis C.
  • Analysis of clinical trial data and real-world evidence for direct-acting antivirals in children.
  • Synthesis of information on emerging antiviral therapies and their applicability to pediatric patients.

Main Results:

  • Current pediatric HCV treatment is evidence-based but limited compared to adults.
  • Newer DAAs show promise for improved efficacy and tolerability in children.
  • Further research and clinical trials are needed to establish optimal DAA regimens for pediatric use.

Conclusions:

  • Direct-acting antivirals are transforming hepatitis C treatment globally.
  • Adapting novel antiviral therapies for pediatric use is a critical unmet need.
  • This review provides a foundation for understanding current and future pediatric hepatitis C management.

Keywords:
ChildrenDirect acting antiviralsHepatitis CHost targeting agentsTreatment

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.8K
Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

686

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
42
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
377
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
335
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
620
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.6K
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
28